Groff North America
Pipeline Background

Therapeutic Pipeline

We are advancing a targeted portfolio of botanical therapeutics addressing high-unmet-need indications in neurology, oncology, and inflammation, leveraging our proprietary botanical APIs.

Development Status

Current progress of our lead candidates.

Neurology

Peripheral Neuropathy

GRF-101

A novel botanical formulation targeting nerve pain pathways with enhanced bioavailability.

DiscPrePh1Ph2Ph3
Oncology

Solid Tumors

GRF-301

Adjuvant therapy to enhance efficacy of standard chemotherapy regimens.

DiscPrePh1Ph2Ph3
Inflammation

Autoimmune Disorders

GRF-405

Modulating immune response through specific receptor targeting.

DiscPrePh1Ph2Ph3
DNA Background
Accelerated Clinical Strategy

Mitigating Clinical Risk

By pairing our 100% homozygous botanical APIs with established delivery technologies, we aim to bypass early-stage formulation hurdles. This strategy leverages known safety profiles to accelerate clinical milestones.

Key Advantages

  • Proprietary Genetic Library (300+ Cultivars)
  • Established Delivery Systems
  • Federal DEA Manufacturing Licenses
  • Pharmaceutical Consistency (DUS Standards)